產品描述: | Mirin是有效的Mre11–Rad50–Nbs1(MRN)復合體抑制劑,能夠抑制Mre11相關的外切酶活性。Mirin 可抑制MRN依賴的ATM的激活 |
靶點: |
MRN;ATM;ATM/ATR |
體外研究: |
Mirin抑制了DSB誘導的ATM活化,ATM依賴性的下游靶點Nbs1和Chk2的磷酸化以及MRN依賴性的ATM在Ser1981位點的自磷酸化。Mirin還抑制了TOSA4細胞的G2檢查點以及HEK293細胞中同源依賴性的DNA修復。在整合有HPV16 (SiHa)的細胞中,Mirin增加了HPV episomes對PA25的敏感性,使PA25的IC50降低了5倍。mirin的預處理還降低了cisplatin處理的293細胞的細胞活性并且抑制了增殖細胞核抗原的表達 |
體內研究: |
Mirin in nanoparticles resulted in a sharp impairment of tumor growth, associated with DDR activation, p53 accumulation, and cell death. |
細胞實驗: |
Cell lines: HEK 293 cells Concentrations: 100 μM Incubation Time: 24 h Method: 人源胚胎腎細胞HEK293用添加有5熱滅活胎牛血清,青霉素(100 U/mL),鏈霉素(100 mg/mL)的RPMI-1640培養(yǎng)基在含有5% CO2,37 °C的條件下進行培養(yǎng)。每個48小時更換新的培養(yǎng)基。細胞接種到96-孔板上,用mirin(100 μM)預處理一小時,然后加入cisplatin后再孵育8小時和24小時。然后利用EZ-Cytox cell viability assay kit進行MTT測試,MTT的降低值用酶標儀在450 nm波長下進行測定。 |
參考文獻: |
1. Dupré A, et al. A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol. 2008, 4(2), 119-125. 2. Edwards TG, et al. DNA damage repair genes controlling human papillomavirus (HPV) episome levels under conditions of stability and extreme instability. PLoS One. 2013, 8(10):e75406. 3. Kim YJ, et al. Expression of the Mre11-Rad50-Nbs1 complex in cisplatin nephrotoxicity. Environ Toxicol Pharmacol. 2015, 40(1), 12-17. 4. Petroni M, et al. MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. Cell Death Dis. 2018 Aug 30;9(9):895. |
溶解性: |
soluble in DMSO |
保存條件: |
-20℃ |
配置溶液濃度參考: |
|
1mg |
5mg |
10mg |
1 mM |
4.54 ml |
22.702 ml |
45.403 ml |
5 mM |
0.908 ml |
4.54 ml |
9.081 ml |
10 mM |
0.454 ml |
2.27 ml |
4.54 ml |
50 mM |
0.091 ml |
0.454 ml |
0.908 ml |
|
注意: |
部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。 |